In this section
MACC Fund Center for Cancer and Blood Disorders
- Programs and services
- Conditions
- Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- Alpha Beta T-cell and B-cell depleted allogeneic transplantation followed by Blinatumomab therapy for high-risk B-Acute Lymphoblastic Leukemia pilot study
- Blinatumomab bridging therapy in high-risk B-ALL clinical trial
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
- Patient stories
- Locations
- Our specialists
- For medical professionals
- Contact us
- Diet and nutritional care
- Our philanthropic partners
- Get a second opinion
- Patient family information
Alpha Beta T-cell and B-cell depleted allogeneic transplantation followed by Blinatumomab therapy for high-risk B-Acute Lymphoblastic Leukemia pilot study
Children’s Wisconsin is currently enrolling on this pilot study. This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by Blinatumomab therapy for high-risk B cell Acute Lymphoblastic Leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing. This multi-institutional study will be limited to 25 (estimated 10-15 per stratum) evaluable children, adolescents and young adults with B-ALL, that have experienced a relapse or have high-risk disease. Patients must be enrolled on our phase 2 Blinatumomab bridging study in order to be eligible for this study.
ClinicalTrials.gov identifier (NCT number): NCT04746209
Investigator and Study Chair: Rachel Phelan, MD, MPH
For more information contact: Tara Murphy | Clinical Research RN | 414-266-6471
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?